GenomeWeb published an update (scroll down)on Helicos on Friday April 16. Full Year Revenues for fiscal 2009 were $3M and although R&D and Admin expenses were cut the Net Loss for the Year was $28M.

Helicos has been working with the investment bank Thomas Weisel Partners since last summer to explore strategic alternatives.On April 14 the Company received a notice from NASDAQ a Notice of Delisting because the stock price fell under $1.00 for a minimum of 10 consecutive business days and Helicos needs to regain compliance by October 11.2010.

With the stock trading at $0.79 and a market cap of $57M an equity raise is too dilutive. A strategic partner must be found.

Helicos Eyeing Potential MDx Applications as FY 2009 Revenues Hit $3M | GenomeWeb Daily News | Sequencing | GenomeWeb

Pin It on Pinterest